Enabling Protein Degradation Drug Discovery

Home » News & Events » Archives for

We’re hiring!

Posted on June 17th, 2020 in News
Senior Scientist/Principal Scientist Proteomics Click here for more details

COVID-19 Update: Ubiquigent fully operational

Posted on April 30th, 2020 in News
Following the announcement by the UK Prime Minister and Scotland’s First Minister on the 23rd March we took the decision to temporarily close our laboratory with all staff transitioning to home working.  During this period we developed a plan that… Read more

DUBprofiler-Cell™ – target validation and compound-target engagement

Posted on January 30th, 2020 in News
Ubiquigent launches new service to facilitate target validation of deubiquitylase (DUB) enzymes and determine compound-DUB target engagement and selectivity of novel compounds in Cells Dundee, UNITED KINGDOM, 30th January 2020: Ubiquigent Limited (Ubiquigent) announced today the launch of an exciting… Read more

LEO Pharma Enters into Option Agreement with Ubiquigent for Access to Novel Compounds

Posted on October 30th, 2019 in News
Ballerup, DENMARK and Dundee, UNITED KINGDOM, 30th October 2019: Ubiquigent Limited (Ubiquigent) and LEO Pharma A/S announced today that they have entered into an option agreement granting LEO Pharma access to two novel compounds. Today’s announcement follows on from an… Read more

Targeted Protein Degradation

Posted on October 21st, 2019 in News
Ubiquigent's Scientific and Business Development Director Jason Brown will be presenting the latest developments regarding our PROTAC and molecular glue targeted protein degradation proteomics services (DUBprofiler-Cell™ and PROTEOMEprofiler™) and DUB drug discovery biology and chemistry hit-to-lead platform at the Targeted… Read more

Dorian Therapeutics Accesses Novel Compound Library from Ubiquigent

Posted on May 23rd, 2019 in News
Dundee, UK, 23rd May 2019: Ubiquigent Limited, a company focused on enabling and supporting ubiquitin system-focused drug discovery, announced today that it had entered into an agreement with Dorian Therapeutics to provide access to one of its novel small molecule… Read more

CHI Drug Discovery Chemistry, San Diego 8-12th April

Posted on April 4th, 2019 in Events
Targeting Deubiquitylases (DUBs): Opportunities for Collaborative Drug Discovery Ubiquigent's Scientific and Business Development Director, Dr Jason Brown, will be presenting at the CHI Drug Discovery Chemistry conference in San Diego on Thursday 11th April 2019 at 11:45am. We will discuss… Read more

European Protein Degradation Congress, 22nd-23rd May, Basel.

Posted on March 1st, 2019 in Events
Jason Brown will be presenting at the upcoming European Protein Degradation Congress (May 22nd-23rd, Basel). Modulating protein degradation pathways potentially offers us new ways to address challenging drug targets.  Jason Brown will be presenting on our approaches in this field at… Read more

Targeted Protein Degradation, 24th – 25th October, Boston

Posted on October 10th, 2018 in Events
Ubiquigent will be attending the upcoming Targeted Protein Degradation conference in Boston, MA. Jason Brown (Scientific and Business Development Director) will also be presenting on day one of the conference at 10am: 'Case Study: A chemistry and Assay Platform for… Read more

Rapid Identification of Redox Cycling Compounds – REDOXprofiler™

Posted on August 22nd, 2018 in News
Dundee, UK – 22nd August 2018: Ubiquigent Limited, a company specialising in providing ubiquitin cell-signalling system drug discovery services, research tools and novel targeted chemistry, announced today that it has launched REDOXprofiler™.  The new service, validated following a collaboration with… Read more